These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33082101)

  • 1. Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.
    Urbán L; Dóczi R; Vodicska B; Tihanyi D; Horváth M; Kormos D; Takács I; Pápai-Székely Z; Póka-Farkas Z; Várkondi E; Schwáb R; Hegedüs C; Vályi-Nagy I; Peták I
    Clin Lung Cancer; 2021 Jan; 22(1):e112-e115. PubMed ID: 33082101
    [No Abstract]   [Full Text] [Related]  

  • 2. Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC.
    van Veggel B; de Langen AJ; Hashemi SMS; Monkhorst K; Heideman DAM; Thunnissen E; Smit EF
    J Thorac Oncol; 2018 Aug; 13(8):1222-1226. PubMed ID: 29702285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma.
    Zeng L; Zhang Y; Yang N
    J Thorac Oncol; 2018 Jun; 13(6):e93-e95. PubMed ID: 29793651
    [No Abstract]   [Full Text] [Related]  

  • 4. Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.
    Zeng L; Xia C; Zhang Y; Yang N
    J Thorac Oncol; 2019 Apr; 14(4):e70-e72. PubMed ID: 30922580
    [No Abstract]   [Full Text] [Related]  

  • 5. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
    Sato M; Matsui A; Shimoyama Y; Omote N; Morise M; Hase T; Tanaka I; Suzuki K; Hasegawa Y
    Intern Med; 2018 Dec; 57(23):3429-3432. PubMed ID: 30101911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
    Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afatinib Achieved Remarkable Disease Control in a Chinese Patient With Lung Adenocarcinoma Harboring Rare EGFR Exon 18-25 Kinase Domain Duplication.
    Wang XF; Zhao QT; Chen C
    Am J Ther; 2020; 27(5):e535-e537. PubMed ID: 31567148
    [No Abstract]   [Full Text] [Related]  

  • 8. Durable Response of Low-Dose Afatinib plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation.
    Fang W; Huang Y; Gan J; Shao YW; Zhang L
    J Thorac Oncol; 2019 Oct; 14(10):e220-e221. PubMed ID: 31558231
    [No Abstract]   [Full Text] [Related]  

  • 9. A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.
    Li S; Zhao J; Wang Q
    J Thorac Oncol; 2018 Jun; 13(6):e97-e101. PubMed ID: 29501421
    [No Abstract]   [Full Text] [Related]  

  • 10. Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L.
    Niogret J; Coudert B; Boidot R
    J Thorac Oncol; 2018 Jul; 13(7):e113. PubMed ID: 29935845
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
    BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.
    Liang SK; Ko JC; Yang JC; Shih JY
    Lung Cancer; 2019 Jul; 133():103-109. PubMed ID: 31200815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afatinib response in a lung adenocarcinoma with novel compound S720F+L861R mutation in EGFR.
    Zhang X; Jiang W; Yang N; Zhang Y
    Lung Cancer; 2020 Oct; 148():170-172. PubMed ID: 32660759
    [No Abstract]   [Full Text] [Related]  

  • 14. Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation.
    Yang X; Huang C; Chen R; Zhao J
    Clin Lung Cancer; 2020 Jul; 21(4):e258-e260. PubMed ID: 32146032
    [No Abstract]   [Full Text] [Related]  

  • 15. Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib.
    Yamaoka T; Ohba M; Matsunaga Y; Tsurutani J; Ohmori T
    J Vis Exp; 2019 Jun; (148):. PubMed ID: 31305510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature.
    Shi Y; Wang M
    Thorac Cancer; 2018 Dec; 9(12):1788-1794. PubMed ID: 30379401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Case of Advanced Lung Adenocarcinoma Harboring an Epidermal Growth Factor Receptor(EGFR) Exon 20 Insertion, D770_N771insSVD.
    Oyamada Y; Wada S; Fujimoto K
    Gan To Kagaku Ryoho; 2021 Jun; 48(6):845-847. PubMed ID: 34139737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report.
    Fang YF; Liu PC
    Thorac Cancer; 2021 Dec; 12(24):3429-3432. PubMed ID: 34729927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.
    He M; Capelletti M; Nafa K; Yun CH; Arcila ME; Miller VA; Ginsberg MS; Zhao B; Kris MG; Eck MJ; Jänne PA; Ladanyi M; Oxnard GR
    Clin Cancer Res; 2012 Mar; 18(6):1790-7. PubMed ID: 22190593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.